Abstract: Therapeutic agents and methods for treating and diagnosing leukemia are provided. Such agents comprises monoclonal antibody M195, a polypeptide capable of binding to the antigen of M195, or a chimeric antibody such a peptide, conjugated to a cytotoxic agent, e.g. a radioisotope or alone. Methods for delivering genetic information to a targeted cell is also provided.

Abstract: This invention provides catalytic molecules capable of cleaving target nucleotide sequences. More specifically, the invention provides an endonuclease having nucleotide sequences which are of sufficient length to allow hybridisation to a target nucleotide sequence desired to be cleaved. The endonuclease contains a catalytic region comprising ribonucleotides and/or deoxyribonucleotides, or derivatives thereof which act to cleave a phosphodiester bond of the substrate nucleotide sequence. The catalytic region comprises nucleotides or derivatives thereof which are linked by linking groups which may comprise ribonucleotides, deoxyribonucleotides or combinations thereof.The endonucleases of the invention are useful in the cleavage of target RNAs associated with disease in humans and animals and in the inactivation of RNA transcripts in eukaryotic and prokaryotic cells, as well as the cleavage of RNA transcripts in-vitro.

Abstract: The subject invention provides non-glycosylated, biologically active polypeptides which comprise the vWF (von Willebrand Factor) GP1b binding domain. These polypeptides may be used to inhibit platelet adhesion and aggregation in the treatment of subjects with conditions such as cerebrovascular disorders and cardiovascular disorders. This invention also provides expression plasmids encoding these polypeptides as well as methods of producing by transforming a bacterial cell and recovering such polypeptides. In addition, the subject invention provides methods of treating and preventing cerebrovascular, cardiovascular and other disorders using these polypeptides to inhibit platelet aggregation.

Abstract: This invention provides a method for preserving cells which comprises the steps of (a) suspending cells in a physiologically-acceptable, isotonic medium; and (b) fixing the cells so suspended at a temperature of less than about 10.degree. C. under sufficiently hypertonic conditions so as to disperse the cells in a single, unagglutinated state, thereby preserving cells. This invention also provides a method for detecting cells separated from a sample which have been preserved according to the aforementioned method. This invention also provides a method for visualizing cells. Also provided is a method for detecting a metabolic process in cells present in a sample. This invention also provides a method for detecting the presence of rare cells in a sample which specifically possess on their surfaces a moiety recognized by a known ligand comprising preserving cells separated from the sample according to the aforementioned method for preserving cells.

Abstract: This invention is directed to improved catalytic compounds, minizymes and miniribozymes, capable of hybridizing with a target RNA to be cleaved. The minizymes and miniribozymes and compositions of the present invention may be used in vitro or in vivo. They may be used as diagnostic or therapeutic agents.

Abstract: This invention provides catalytic molecules capable of cleaving target nucleotide sequences. More specifically, the invention provides an endonuclease having nucleotide sequences which are of sufficient length to allow hybridisation to a target nucleotide sequence desired to be cleaved. The endonuclease contains a catalytic region comprising ribonucleotides and/or deoxyribonucleotides, or derivatives thereof which act to cleave a phosphodiester bond of the substrate nucleotide sequence. The catalytic region comprises nucleotides or derivatives thereof which are linked by linking groups which may comprise ribonucleotides, deoxyribonucleotides or combinations thereof.The endonucleases of the invention are useful in the cleavage of target RNAs associated with disease in humans and animals and in the inactivation of RNA transcripts in eukaryotic and prokaryotic cells, as well as the cleavage of RNA transcripts in-vitro.

Abstract: The present invention provides a compound having the structure: ##STR1## wherein R.sub.1 is a saturated or unsaturated linear or branched chain alkyl group, or a cholestanyl group; wherein R.sub.2 is a 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 4-hydroxyphenyl, 4-(arylalkyloxy)phenyl, 3,4-dihalophenyl, 4-hydroxy-3,5-dihalophenyl, 4-azidophenyl or 4-halophenyl group; wherein R.sub.3 is H, a linear or branched chain alkyl or alkenyl group, or a phenyl, 2-azidophenyl, 3-azidophenyl, 4-azidophenyl group, or an a alkenylacyl, 3-amino-3-butylpropyl, N-[N-(N-{4-azidobenzoyl}aminopropyl) aminopropyl], cis- or trans-cinnamyl, 2-amino-2-[(4'-azidophenyl)acetyl, (trifluoromethyl)aminoacetyl or D- or L-arginyl group bonded through the .alpha.-carbonyl moiety thereof; R.sub.4 is H, or a linear or branched chain alkyl group; wherein R.sub.5, R.sub.6 and R.sub.

Abstract: An improved and efficient process for the production of recombinant human insulin by folding of a proinsulin hybrid polypeptide is provided.

Abstract: This invention provides a recombinant fowlpox virus comprising a foreign DNA sequence inserted into the fowlpox virus genomic DNA, wherein the foreign DNA sequence is inserted within a 4.2 kB EcoRI fragment of the fowlpox virus genomic DNA and is capable of being expressed in a fowlpox virus infected host cell. The invention further provides homology vectors, vaccines and methods of immunization.

Abstract: Encoded combinatorial chemistry is provided, where sequential synthetic schemes are recorded using organic molecules, which define choice of reactant, and stage, as the same or different bit of information. Various products can be produced in the multi-stage synthesis, such as oligomers and synthetic non-repetitive organic molecules. Conveniently, nested families of compounds can be employed as identifiers, where number and/or position of a substituent define the choice. Alternatively, detectable functionalities may be employed, such as radioisotopes, fluorescers, halogens, and the like, where presence and ratios of two different groups can be used to define stage or choice. Particularly, pluralities of identifiers may be used to provide a binary or higher code, so as to define a plurality of choices with only a few detachable tags. The particles may be screened for a characteristic of interest, particularly binding affinity, where the products may be detached from the particle or retained on the particle.

Abstract: This invention is directed to improved catalytic compounds, minizymes and miniribozymes, capable of hybridizing with a target RNA to be cleaved. The minizymes and miniribozymes and compositions of the present invention may be used in vitro or in vivo. They may be used as diagnostic or therapeutic agents.

Abstract: According to the present invention, the operating amount of the brake is detected, and the target value of the regenerative torque is set in accordance with the detected operating amount. In the meantime, the change in the detected operating amount along with time is detected, and the rise speed of the regenerative torque is set in accordance with the detected change along with time. The regenerative torque is controlled in accordance with the set target value of the regenerative torque and the set rise speed.

Abstract: This invention is directed to improved catalytic compounds, hammerhead ribozymes, capable of hybridizing with a target RNA to be cleaved. These improved compounds have optimized stems (X)m * (X)m', loops (X)b and hybridizing arms. The invention is also directed to compositions for enhanced RNA cleavage which comprise a first synthetic non-naturally occurring oligonucleotide compound which comprises nucleotides whose sequence defines a conserved catalytic region and nucleotides whose sequence is capable of hybridizing with a predetermined target sequence and a second synthetic non-naturally occurring oligonucleotide which does not contain the predetermined target sequence and is complementary to at least a portion of the first oligonucleotide compound. The invention is also directed to synthetic non-naturally occurring oligonucleotide compounds embedded in a tRNA. The ribozymes and compositions of the present invention may be used in vitro or in vivo. They may be used as diagnostic or therapeutic agents.

Abstract: An image pickup system including an image pickup device (4) for taking an image from an object (1) containing a periodic pattern and outputting an image signal (5), a zoom lens (2) for forming an object image on the image pickup device, a moire amount detection circuit (10) for detecting an amount of moire from the image signal (5), and an imaging magnification control circuit including a differentiating circuit (18) provided for setting a magnification of the zoom lens (2) and finely adjusting the magnification of the zoom lens (2) to allow the amount of moire detected by the moire amount detection circuit (10) to become below the setting value, a positive/negative determination circuit (20), a system controller (22), and a ROM (24).

Abstract: A thin film transistor LCD and a fabricating method therefor.

Abstract: The present invention provides a rod antenna for use in a portable transmitting/receiving apparatus. The rod antenna is housed in a case of the portable transmitting/receiving apparatus so as to be freely inserted thereinto and drawn therefrom and is electrically connected to a feeder section provided in the case. The rod antenna includes an antenna element having a column formed of insulating material and a conductive film formed on an outer surface of the column along a longitudinal direction of the column so as to have a predetermined length corresponding to transmitted/received waves.

Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.

Abstract: This invention provides an aggregate of a compound capable of forming helical structures such that the aggregate is capable of achieving a specific rotation of at least 100,000.degree. for plane polarized light having a wavelength of 589 nm.

Abstract: A halogen-free flame retardant epoxy resin composition containing (A) a bisphenol A type epoxy resin, (B) a curing agent, (C) red phosphorus particles each of which is covered with a covering layer, at least the outermost layer of which is formed of a resin, and (D) an inorganic filler.

Abstract: This invention provides an isolated nucleic acid molecule encoding a protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells. The nucleic acid molecule may include a DNA molecule or a cDNA molecule. This invention further provides a gene transfer vector including the nucleic acid molecule operably linked to a promoter of RNA transcription. The vector may be a plasmid or a viral vector. This invention further provides a host vector system including the gene transfer vector in a suitable host cell. The transformed yeast or a stably transformed mammalian cell. This invention further provides a method of producing a T cell surface protein necessary for T cell activation of B cells which includes growing the host vector system under conditions permitting production of the protein, followed by recovering the protein so produced.